secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001437749-23-013949
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences Q1 net loss narrows to $9.8M; $65M private placement with Executive Chairman
--------------------------------------------------------------------------------

- GAAP net loss of $9.8M vs $17.3M YoY; non-GAAP net loss of $8.6M vs $14.2M.
- Cash and equivalents $54.1M as of March 31, 2023, up from $12.7M a year ago.
- Entered $65M private placement with Executive Chairman Robert Duggan, canceling all indebtedness.
- Appointed Dr. Gan Dunnington as Chief Medical Officer, Cardiac Surgery.
- Completed FDA pre-submission for nsPFA surgical ablation clamp; advancing preclinical studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774923013949/0001437749-23-013949-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774923013949/plse20230510_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-013949

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer